INSL6

Summary

INSL6 (insulin like 6, HGNC:6089) is a protein-coding gene on chromosome 9p24.1, encoding Insulin-like peptide INSL6 (Q9Y581). May have a role in sperm development and fertilization.

The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization.

Source: NCBI Gene 11172 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 623 total — 2 pathogenic, 4 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_007179

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6089
Approved symbol	INSL6
Name	insulin like 6
Location	9p24.1
Locus type	gene with protein product
Status	Approved
Aliases	RIF1
Ensembl gene	ENSG00000120210
Ensembl biotype	protein_coding
OMIM	606414
Entrez	11172

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000381641, ENST00000510407, ENST00000649639

RefSeq mRNA: 1 — MANE Select: NM_007179 NM_007179

CCDS: CCDS6458

Canonical transcript exons

ENST00000381641 — 2 exons

Exon	Start	End
ENSE00001489323	5163868	5164265
ENSE00001489329	5185314	5185639

Expression profiles

Bgee: expression breadth ubiquitous, 152 present calls, max score 88.50.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0364 / max 21.6521, expressed in 10 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99814	0.0328	10
205419	0.0036	2

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.50	gold quality
left testis	UBERON:0004533	83.39	gold quality
right testis	UBERON:0004534	83.25	gold quality
calcaneal tendon	UBERON:0003701	82.38	gold quality
testis	UBERON:0000473	81.19	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	74.90	gold quality
monocyte	CL:0000576	73.01	gold quality
mononuclear cell	CL:0000842	72.80	gold quality
leukocyte	CL:0000738	70.89	gold quality
popliteal artery	UBERON:0002250	70.40	gold quality
tibial artery	UBERON:0007610	70.35	gold quality
aorta	UBERON:0000947	67.67	gold quality
tendon	UBERON:0000043	67.27	gold quality
ascending aorta	UBERON:0001496	64.69	gold quality
descending thoracic aorta	UBERON:0002345	64.62	gold quality
thoracic aorta	UBERON:0001515	64.40	gold quality
left coronary artery	UBERON:0001626	61.82	gold quality
adrenal tissue	UBERON:0018303	60.78	gold quality
skin of abdomen	UBERON:0001416	60.44	gold quality
coronary artery	UBERON:0001621	60.38	gold quality
skin of leg	UBERON:0001511	60.35	gold quality
bone marrow cell	CL:0002092	59.63	gold quality
ectocervix	UBERON:0012249	59.63	gold quality
adult organism	UBERON:0007023	59.24	silver quality
tibial nerve	UBERON:0001323	59.03	gold quality
right coronary artery	UBERON:0001625	58.41	gold quality
subcutaneous adipose tissue	UBERON:0002190	58.40	gold quality
right ovary	UBERON:0002118	58.31	gold quality
zone of skin	UBERON:0000014	57.74	gold quality
right lung	UBERON:0002167	57.59	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6075	yes	593.60
E-MTAB-6678	no	4.05
E-ANND-3	no	3.24

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• Myocardial Infarction-Induced INSL6 Decrease Contributes to Breast Cancer Progression. (PMID:36798786)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Insl6	ENSMUSG00000050957
rattus_norvegicus	Insl6	ENSRNOG00000015868

Paralogs (3): RLN2 (ENSG00000107014), RLN1 (ENSG00000107018), INSL4 (ENSG00000120211)

Protein

Protein identifiers

Insulin-like peptide INSL6 — Q9Y581 (reviewed: Q9Y581)

Alternative names: Relaxin/insulin-like factor 1

All UniProt accessions (2): A0A3B3ITZ2, Q9Y581

UniProt curated annotations — full annotation on UniProt →

Function. May have a role in sperm development and fertilization.

Subcellular location. Secreted.

Tissue specificity. Testis specific.

Similarity. Belongs to the insulin family.

RefSeq proteins (1): NP_009110* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016179	Insulin-like	Domain
IPR017100	Insulin-like_pep_6	Family
IPR022353	Insulin_CS	Conserved_site
IPR036438	Insulin-like_sf	Homologous_superfamily
IPR051042	Repro_Hormone_Insulin-like	Family

Pfam: PF00049

UniProt features (11 total): disulfide bond 3, peptide 2, propeptide 2, signal peptide 1, chain 1, sequence conflict 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y581-F1	54.46	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 33–179, 45–192, 178–183

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 92 (showing top): HATADA_METHYLATED_IN_LUNG_CANCER_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, GOMF_SIGNALING_RECEPTOR_BINDING, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN, WEBER_METHYLATED_HCP_IN_SPERM_DN, GOMF_HORMONE_ACTIVITY, GOMF_SIGNALING_RECEPTOR_REGULATOR_ACTIVITY, BRUINS_UVC_RESPONSE_LATE, PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_UP, DURAND_STROMA_NS_UP, ATF2_S_UP.V1_UP, CAHOY_ASTROGLIAL, GSE13522_WT_VS_IFNAR_KO_SKIN_UP, GSE14699_DELETIONAL_TOLERANCE_VS_ACTIVATED_CD8_TCELL_DN

GO Biological Process (1): signal transduction (GO:0007165)

GO Molecular Function (1): hormone activity (GO:0005179)

GO Cellular Component (1): extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

462 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
INSL6	INSL4	Q14641	979
INSL6	RLN3	Q8WXF3	771
INSL6	INSL5	Q9Y5Q6	742
INSL6	INSL3	P51460	704
INSL6	RXFP3	Q9NSD7	662
INSL6	RXFP4	Q8TDU9	639
INSL6	RXFP1	Q9HBX9	625
INSL6	RXFP2	Q8WXD0	582
INSL6	RLN2	P04090	559
INSL6	SRY	Q05066	504
INSL6	RLN1	P04808	475
INSL6	C10orf120	Q5SQS8	475
INSL6	C5orf47	Q569G3	445
INSL6	PLGRKT	Q9HBL7	434
INSL6	SVOP	Q8N4V2	430

IntAct

6 interactions, top by confidence:

A	B	Type	Score
INSL6	POTEF	psi-mi:“MI:0914”(association)	0.530
INSL6	MYCBP2	psi-mi:“MI:0914”(association)	0.530
INSL6	AP3B1	psi-mi:“MI:0914”(association)	0.350
RAB39B	RAB5A	psi-mi:“MI:0914”(association)	0.350
	PIK3R2	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): WBP5 (Affinity Capture-MS), UBAC1 (Affinity Capture-MS), GID4 (Affinity Capture-MS), RNF123 (Affinity Capture-MS), WDR26 (Affinity Capture-MS), ZMYND19 (Affinity Capture-MS), MKLN1 (Affinity Capture-MS), PPM1A (Affinity Capture-MS), ACIN1 (Affinity Capture-MS), MAEA (Affinity Capture-MS), RANBP10 (Affinity Capture-MS), ARMC8 (Affinity Capture-MS), RMND5A (Affinity Capture-MS), LRP2 (Affinity Capture-MS), GID8 (Affinity Capture-MS)

ESM2 similar proteins: A2BDC9, A6NM62, E9Q793, O08999, O35806, O55233, O95813, P13207, P22389, P23499, P23943, P24054, P29560, P35054, P70041, P86275, Q07G34, Q14515, Q17R60, Q2Q0I9, Q3UU94, Q3V1M1, Q4V9H3, Q4ZHG4, Q5K027, Q5NRP8, Q5NRP9, Q5NRQ1, Q5QQ37, Q68CR7, Q6WRH9, Q6WRI0, Q701R2, Q701R3, Q701R4, Q76K27, Q8CG19, Q8JIR8, Q8JZQ0, Q8R1W8

Diamond homologs: P01347, P01348, P04090, P04808, P19884, P22969, P47932, P51453, P51454, P51455, P51456, Q5CZK6, Q64171, Q9MYK8, Q9TRM8, Q9Y581, Q32L79, Q9QY05, Q9WV41, P11952

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

623 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	4
Uncertain significance	362
Likely benign	159
Benign	54

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
14664	NM_004972.4(JAK2):c.1615_1616inv (p.Lys539Leu)	Pathogenic
29763	NM_004972.4(JAK2):c.1849G>A (p.Val617Ile)	Pathogenic
2136731	NM_004972.4(JAK2):c.2600G>A (p.Arg867Gln)	Likely pathogenic
2504150	NM_004972.4(JAK2):c.226+1G>T	Likely pathogenic
3391058	NM_004972.4(JAK2):c.3284C>T (p.Pro1095Leu)	Likely pathogenic
4813688	NM_004972.4(JAK2):c.2813G>A (p.Arg938Gln)	Likely pathogenic

SpliceAI

421 predictions. Top by Δscore:

Variant	Effect	Δscore
9:5164266:C:CC	acceptor_gain	1.0000
9:5126326:GTTTT:G	acceptor_loss	0.9900
9:5126327:TTTTA:T	acceptor_loss	0.9900
9:5126328:TTTAG:T	acceptor_loss	0.9900
9:5126329:TTA:T	acceptor_loss	0.9900
9:5126330:TA:T	acceptor_loss	0.9900
9:5126331:A:AC	acceptor_loss	0.9900
9:5126331:A:AG	acceptor_gain	0.9900
9:5126332:G:GC	acceptor_loss	0.9900
9:5126332:G:GG	acceptor_gain	0.9900
9:5126332:GGA:G	acceptor_gain	0.9900
9:5126442:A:G	donor_gain	0.9900
9:5126445:AGGT:A	donor_loss	0.9900
9:5126446:GG:G	donor_loss	0.9900
9:5126447:G:GA	donor_loss	0.9900
9:5126448:T:A	donor_loss	0.9900
9:5126682:A:AG	acceptor_gain	0.9900
9:5126683:G:GG	acceptor_gain	0.9900
9:5126683:GATCT:G	acceptor_gain	0.9900
9:5164264:CA:C	acceptor_gain	0.9900
9:5185312:AC:A	donor_loss	0.9900
9:5185313:C:A	donor_loss	0.9900
9:5126678:TTACA:T	acceptor_loss	0.9800
9:5126679:TACAG:T	acceptor_loss	0.9800
9:5126680:ACAGA:A	acceptor_loss	0.9800
9:5126681:CAG:C	acceptor_loss	0.9800
9:5126682:A:C	acceptor_loss	0.9800
9:5164262:GACA:G	acceptor_gain	0.9800
9:5126325:T:A	acceptor_loss	0.9600
9:5126683:GAT:G	acceptor_gain	0.9600

AlphaMissense

1377 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:5185453:C:A	W50C	0.986
9:5185453:C:G	W50C	0.986
9:5164007:C:G	C183S	0.981
9:5164008:A:T	C183S	0.981
9:5163992:A:G	L188P	0.975
9:5164022:C:G	C178S	0.974
9:5164023:A:T	C178S	0.974
9:5164008:A:G	C183R	0.968
9:5185469:C:G	C45S	0.968
9:5185470:A:T	C45S	0.968
9:5164023:A:G	C178R	0.967
9:5185493:A:G	L37S	0.965
9:5163981:A:G	C192R	0.963
9:5163992:A:T	L188H	0.963
9:5164048:T:A	R169S	0.962
9:5164048:T:G	R169S	0.962
9:5185469:C:T	C45Y	0.961
9:5185505:C:G	C33S	0.961
9:5185506:A:T	C33S	0.961
9:5164019:C:G	C179S	0.960
9:5164020:A:T	C179S	0.960
9:5164021:A:C	C178W	0.959
9:5164020:A:G	C179R	0.957
9:5164007:C:T	C183Y	0.956
9:5164018:A:C	C179W	0.956
9:5163983:G:T	A191E	0.955
9:5185503:C:A	G34C	0.955
9:5164066:C:A	W163C	0.954
9:5164066:C:G	W163C	0.954
9:5185470:A:G	C45R	0.954

dbSNP variants (sampled 300 via entrez): RS1000043085 (9:4995488 T>G), RS1000051902 (9:5143137 A>C), RS1000062956 (9:5131229 A>G), RS1000080672 (9:5162885 G>C), RS1000084644 (9:5085251 C>A,T), RS1000092136 (9:5040011 T>G), RS1000096910 (9:5063855 A>G), RS1000126932 (9:5131574 A>T), RS1000138589 (9:5088193 A>G), RS1000156895 (9:5116522 G>C), RS1000158426 (9:5115798 A>G), RS1000179472 (9:5105379 G>A), RS1000216432 (9:5035466 T>C), RS1000258206 (9:5120425 T>A), RS1000279916 (9:5101454 G>A)

Disease associations

OMIM: gene MIM:606414 | disease phenotypes: MIM:133100, MIM:254450, MIM:263300, MIM:600880, MIM:614521, MIM:601626, MIM:600807

GenCC curated gene-disease

Mondo (9): primary familial polycythemia due to EPO receptor mutation (MONDO:0007572), primary myelofibrosis (MONDO:0009692), acquired polycythemia vera (MONDO:0009891), Budd-Chiari syndrome (MONDO:0010947), thrombocythemia 3 (MONDO:0013794), acute myeloid leukemia (MONDO:0018874), inherited susceptibility to asthma (MONDO:0010940), polycythemia (MONDO:0005571), primary ovarian failure (MONDO:0005387)

Orphanet (7): Budd-Chiari syndrome (Orphanet:131), Acute myeloid leukemia (Orphanet:519), Polycythemia vera (Orphanet:729), Primary myelofibrosis (Orphanet:824), Primary familial polycythemia (Orphanet:90042), Polycythemia (Orphanet:98427), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001901	Polycythemia

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000529_4	Ulcerative colitis	1.000000e-06
GCST003264_760	Post bronchodilator FEV1/FVC ratio	2.000000e-07
GCST90002402_103	Platelet count	5.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004713	FEV/FVC ratio
EFO:0004309	platelet count

MeSH disease descriptors (6)

Descriptor	Name	Tree numbers
D006502	Budd-Chiari Syndrome	C06.552.347; C14.907.355.830.925.275
D015470	Leukemia, Myeloid, Acute	C04.557.337.539.275; C15.378.508.539.275
D011086	Polycythemia	C15.378.738
D011087	Polycythemia Vera	C04.588.448.200.500; C15.378.190.250.500; C15.378.190.636.753; C15.378.400.200.500
D055728	Primary Myelofibrosis	C15.378.190.636.765
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs12343867	INSL6, JAK2		0.00	0
rs77375493	INSL6, JAK2		0.00	0

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation	1
testosterone undecanoate	affects cotreatment, increases expression	1
arsenite	decreases methylation, increases expression	1
CGP 52608	affects binding, increases reaction	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Levonorgestrel	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

258 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01558739	PHASE4	COMPLETED	Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
NCT02386800	PHASE4	ACTIVE_NOT_RECRUITING	CINC424A2X01B Rollover Protocol
NCT05853458	PHASE4	TERMINATED	Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
NCT06290765	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
NCT00799461	PHASE3	COMPLETED	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
NCT01178281	PHASE3	COMPLETED	Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
NCT01387763	PHASE3	COMPLETED	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
NCT01773187	PHASE3	TERMINATED	Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT01969838	PHASE3	COMPLETED	Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
NCT02055781	PHASE3	TERMINATED	Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT02087059	PHASE3	COMPLETED	A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
NCT02101268	PHASE3	COMPLETED	Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
NCT03165734	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03755518	PHASE3	TERMINATED	A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT03952039	PHASE3	COMPLETED	An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT04173494	PHASE3	COMPLETED	A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
NCT04551053	PHASE3	TERMINATED	To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551066	PHASE3	TERMINATED	To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04603495	PHASE3	ACTIVE_NOT_RECRUITING	Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04717414	PHASE3	ACTIVE_NOT_RECRUITING	An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT06351631	PHASE3	RECRUITING	A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06468033	PHASE3	RECRUITING	P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06479135	PHASE3	RECRUITING	Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT07357727	PHASE3	RECRUITING	A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT01243944	PHASE3	COMPLETED	Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
NCT01632904	PHASE3	COMPLETED	Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
NCT01645124	PHASE3	TERMINATED	Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
NCT01949805	PHASE3	COMPLETED	Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
NCT02038036	PHASE3	COMPLETED	Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
NCT02218047	PHASE3	COMPLETED	AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
NCT02292446	PHASE3	COMPLETED	Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
NCT02523638	PHASE3	COMPLETED	Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
NCT04116502	PHASE3	RECRUITING	MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04655092	PHASE3	RECRUITING	Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
NCT05198960	PHASE3	RECRUITING	AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
NCT05210790	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05481151	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
NCT06002490	PHASE3	COMPLETED	A Study to Evaluate P1101 in Japanese PV Patients
NCT06033586	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
NCT06093672	PHASE3	RECRUITING	Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera